The global Coxsackievirus Infections Treatment Market Size is currently valued at US$ 5.5 Billion in 2023 and is anticipated to expand at a CAGR of 8.2%. Owing to the technological advances in healthcare the market is likely to propel to US$ 12.1 Billion by 2033.
Coxsackieviruses are non-enveloped viruses of the picornaviridae family and the enterovirus genus with linear single-stranded RNA as their genetic material. These viruses are classified into two groups based on their pathogenicity in mice.
Group A viruses have been linked to skin and mucous membrane infections, which can lead to herpangina, hand-foot-and-mouth disease, and acute hemorrhagic conjunctivitis (AHC).
Unlock growth potential with industry expertise. Download your market sample report now: https://www.futuremarketinsights.com/reports/sample/rep-gb-16445
Group B viruses infect the pancreas, liver, and heart, resulting in pericarditis, hepatitis, myocarditis, and pleurodynia. According to CDC estimates, coxsackievirus infections accounted for approximately 25% of all newborn enterovirus infections documented between 1983 and 2003. Coxsackievirus infects people of all ages; however, children are more vulnerable to the infection. If a mother becomes infected during pregnancy, her foetus or baby is at greater risk of infection. These viruses are discovered in infected patients’ faeces, blister fluid, nasal secretions, and saliva.
Key Takeaways from the Market Study
- As of 2023, the coxsackievirus infection treatment market was valued at US$ 5.5 Billion
- From 2023 to 2033, the coxsackievirus infection treatment industry is poised to grow at an 8.2% CAGR
- By 2033, the coxsackievirus infection treatment market is slated to reach a valuation of US$ 12.1 Billion
- Based on the distribution channel, hospital pharmacy segment accounts for market share of 55% during the forecast period.
- China is poised to yield a CAGR of 7.6% with respect to coxsackievirus infection treatment in 2033
“Growing healthcare spending and growing focus on fast-track approvals for new and upcoming therapies to treat such infections are expected to radically transform the market in the coming years,” comments an analyst at FMI.
Coxsackeivirus Infections Treatment Market Report Available At a Discounted Price: https://www.futuremarketinsights.com/request-discount/rep-gb-16445
Competitive Landscape
Some of the key players present in the global Coxsackievirus Infections Treatment markets are Adimmune Corp., CJ HealthCare Corp., Takeda Pharmaceutical Co Ltd., Shanghai Zerun Biotechnology Co Ltd., Chongqing Zhifei Biological Products Co Ltd., Johnson & Johnson Consumer Inc., GlaxoSmithKline plc., Emergex Vaccines Holdings Ltd, CJ HealthCare Corp., Thermo Fisher Scientific Inc., and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
- In January 2023, Thermo Fisher Scientific Inc. announced that it has completed its acquisition of The Binding Site Group a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital.
- In October 2022, Emergex Vaccines Holding Limited a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces that it has acquired the assets of Zosano Pharma Corporation.
Customize Your Report Now: https://www.futuremarketinsights.com/customization-available/rep-gb-16445
More Valuable Insights Available
FMI, in its new offering, presents an unbiased analysis of the market, presenting historical demand data (2018 to 2022) and forecast statistics for the period of 2023 to 2033.
The study divulges essential insight into Coxsackievirus Infections Treatment market by drug type (acetaminophen, ibuprofen, anti-inflammatory, nucleoside analog antivirals, others) by route of administration (topical, oral, intravenous) by distribution channel (hospital pharmacies, retail pharmacies, online pharmacies) by Region – Global Forecast 2023 to 2033
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs